Monica V. Goldberg

发表

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

D. Getnet, C. Drake, G. Netto, 2009, Cancer research.

Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1

Hua Yu, Drew M. Pardoll, Charles G. Drake, 2007, The Journal of Immunology.

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody*

M. Chiu, Monica V. Goldberg, Di Zhang, 2016, The Journal of Biological Chemistry.

LAG-3 in Cancer Immunotherapy.

C. Drake, Monica V. Goldberg, 2011, Current topics in microbiology and immunology.

Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

J. Desai, H. Lenz, S. Kopetz, 2016 .

Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells 1

D. Getnet, C. Drake, D. Pardoll, 2009, The Journal of Immunology.

Radiotherapy augments the immune response to prostate cancer in a time‐dependent manner

D. Getnet, C. Drake, T. DeWeese, 2008, The Prostate.

A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.

D. Getnet, C. Drake, D. Pardoll, 2010, Molecular immunology.

Antigen-Specific CD4 T Cells Induce Distinct Transcriptional Profiles in Tumor Recognition and Self-Recognition

D. Getnet, C. Drake, D. Pardoll, 2009 .

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

D. Getnet, C. Drake, Lieping Chen, 2007, Blood.

Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study

J. Desai, H. Lenz, S. Kopetz, 2018 .

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

J. Desai, H. Lenz, S. Kopetz, 2017, The Lancet. Oncology.

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1

D. Getnet, C. Drake, D. Pardoll, 2009, The Journal of Immunology.

Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Peter Vogel, Matthew P Smeltzer, David M Gravano, 2022 .

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

D. Getnet, C. Drake, A. D. De Marzo, 2007, The Journal of clinical investigation.

Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity1

D. Getnet, C. Drake, D. Pardoll, 2009, The Journal of Immunology.

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

Christopher M. Jackson, D. Getnet, C. Drake, 2013, Journal of Translational Medicine.

Microenvironment and Immunology Immune InhibitoryMolecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

C. Liu, C. Drake, G. Netto, 2012 .

Stimulated CD8 T Cells Subsets on Activated and Chronically Functionally Distinct LAG-3 and PD-1

D. Getnet, D. Pardoll, D. Vignali, 2009 .

Tc 17 CD 8 T Cells : Functional Plasticity and Subset Diversity 1

D. Getnet, C. Drake, D. Pardoll, 2017 .

This information is current as Subset Diversity Tc 17 CD 8 T Cells : Functional Plasticity and

D. Getnet, D. Pardoll, S. Harris, 2009 .